As the European cannabis market develops, experts say industry players within the space are eager to partner with companies across the pond.

During Cannabis Europa’s first Transatlantic Forum held in Toronto on Tuesday (November 5), attendees heard from industry players across North America and Europe, as well as ones facilitating deals between the two regions due to the emergence of Europe as a force in the global marijuana markets.

On a company partnership level, Steph Sherer, president of the International Cannabis and Cannabinoids Institute, said most of the transatlantic deals she comes across are post-acquisition, and now companies are looking for advice on what to do with their new-found European operations.

Sherer said previously, there was more cash to go around but since “checkbooks are getting smaller,” European companies are in the market to partner with North American players. The challenge, she explained, is making sure the investment is sound.

“If you’re a North American company and looking at European assets, it’s really a question of what are you going to do with that asset and being realistic about the market,” said Sherer.

“Yes, Europe is exciting, it’s big,” she added. “But you can’t just take what happened in Canada and the United States and just add the population of Europe and say ‘This is what’s going to happen here.’”

Sony Gokhale, general counsel for The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF), said significant strides have been made in medical cannabis in Europe in the last year.

Gokhale noted that regions such as Germany, France and the UK have been spearheading the move towards cannabis legalization across the continent.

As part of Supreme Cannabis’ own work to establish its operations in Europe, the company has consulted with regulators to ensure its entrance into the market is carefully planned out, according to Gokhale.

“Without having a thorough understanding of the regulatory regime, we can’t be responsible participants in this industry,” she said.

In Germany, there has been quick development since the country legalized medical cannabis in 2017.

Soon after Germany legalized the drug, there were few patients, even fewer qualified doctors and a lack of insurance coverage, said Marcus Schmidt, director of chemicals and healthcare at Germany Trade and Invest.

However, Schmidt said that during the first half of 2019, 122,000 medical cannabis prescriptions were filled, and that number is growing.

Now, the challenge will come down to supply. Schmidt said cannabis in the country is currently imported from Canada and the Netherlands, but Germany will have its first local harvest in 2020.

Germany’s move to self-sufficiency when it comes to cannabis cultivation is one that Andrew Pucher, the chief corporate development officer at Tilray (NASDAQ:TLRY), said he’s seeing across Europe.

The Tilray executive told investors there is a shift toward localized supplies of medical cannabis, rather than a reliance on a supply chain flow from North America.

For France, political movement has been seen in the form of new clinical trials.

Emmanuelle Fontaine-Domeizel, member of the French National Assembly, said her colleagues voted on an experiment that will test the effects of marijuana on patients over the next two years, according to a translator. Fontaine-Domeizel also spoke of an information mission launched by the French Parliament to gather data that will help foster discussion about cannabis legalization in the country.

Louis Barré, managing director of the Greenfield Global Opportunities Fund, also mentioned some challenges facing European companies and how the challenges could affect the companies’ ability to return value.

“You need to be really mindful of the timing of the maturity of the market,” said Barré. “Are some companies moving too quickly? … Is the European market to be ready for all of this product they’re going to get from Colombia and all the companies in Canada?”

Overall, though, panelists agreed Europe is well-positioned to take a considerable market share of the global marijuana space in the coming years. Stephen Murphy, CEO of cannabis data firm NOBL Group, said the European market is fast moving, both for companies and at the political level.

“When we first started talking about the European markets, there were six markets that were technically legal. Today, it’s just under 20. And that’s in a three and a half year period,” he said.

“We’re also finding that governments are now very much aware of the potential of cannabis not only from an economic perspective, but also from a health, social and from a political perspective.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE: CSI) (OTC: CADMF) (FRA: CWAA) is pleased to announce that all matters submitted to the shareholders of the Company at the Annual General and Special Meeting of the Company’s shareholders held on December 31, 2020 were approved.
In addition, the Company has granted, pursuant to its Equity Incentive Plan, options to purchase 1,500,000 shares of the Company exercisable for a period of 5 years at USD$0.70 per share to the directors, officers and consultants of the Company. The Company has also granted, pursuant to its Equity Incentive Plan, restricted share rights to acquire 1,500,000 shares of the Company to the directors, officers and consultants of the Company. One-half of such restricted share rights shall vest in three months from the grant date and the remaining one-half shall vest in six months from the grant date.
On Behalf of The Board of Directors
Josh Rosenberg
Investor Relations:
1 (604) 398-3378
The CSE has not reviewed, approved or disapproved the content of this press release


Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis extractor, announced today that the Canadian Intellectual Property Office has granted the Company a patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol (“CBD”), and subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique.

Keep reading... Show less